WO2001019394A3 - Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds - Google Patents

Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds Download PDF

Info

Publication number
WO2001019394A3
WO2001019394A3 PCT/US2000/025369 US0025369W WO0119394A3 WO 2001019394 A3 WO2001019394 A3 WO 2001019394A3 US 0025369 W US0025369 W US 0025369W WO 0119394 A3 WO0119394 A3 WO 0119394A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunotherapy
birds
genetically engineered
polyclonal antibody
substantially human
Prior art date
Application number
PCT/US2000/025369
Other languages
French (fr)
Other versions
WO2001019394A2 (en
Inventor
Schooten Wim Van
Jens-Ulrich Buelow
Original Assignee
Therapeutic Human Polyclonals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals filed Critical Therapeutic Human Polyclonals
Priority to AU74918/00A priority Critical patent/AU7491800A/en
Publication of WO2001019394A2 publication Critical patent/WO2001019394A2/en
Publication of WO2001019394A3 publication Critical patent/WO2001019394A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

Substantially human antibodies are provided by genetically modifying a bird. The bird is genetically modified by generating inactive heavy and light chain immunoglobulin loci and integrating at least a portion of the human heavy and light chain immunoglobulin loci. The antibodies purified from serum or egg yolk of immunized bird find use in the treatment of diseases, immunocompromised patients and in case of transplantation.
PCT/US2000/025369 1999-09-15 2000-09-15 Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds WO2001019394A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74918/00A AU7491800A (en) 1999-09-15 2000-09-15 Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15420099P 1999-09-15 1999-09-15
US60/154,200 1999-09-15

Publications (2)

Publication Number Publication Date
WO2001019394A2 WO2001019394A2 (en) 2001-03-22
WO2001019394A3 true WO2001019394A3 (en) 2001-10-04

Family

ID=22550402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025369 WO2001019394A2 (en) 1999-09-15 2000-09-15 Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds

Country Status (2)

Country Link
AU (1) AU7491800A (en)
WO (1) WO2001019394A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001915A (en) 2000-08-03 2004-09-10 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
JP2002316944A (en) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst Human polyclonal antibody composition
PT2314629E (en) 2002-07-18 2014-01-22 Merus B V Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (en) 2003-05-30 2013-06-21 Merus B.V. Fab library for the preparation of a mixture of antibodies
CA2532117C (en) 2003-07-15 2012-07-10 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
PE20081216A1 (en) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc ENHANCED EXPRESSION OF HUMAN OR HUMANIZED IMMUNOGLOBULIN IN NON-HUMAN TRANSGENIC ANIMALS
WO2008151085A1 (en) * 2007-06-01 2008-12-11 Buelow Research Enterprises Llc Compositions and methods for producing antibodies having human idiotypes in transgenic birds
EP2311493A4 (en) * 2008-05-20 2012-09-26 Kaneka Corp Cytotoxic composition
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
HUE045944T2 (en) 2012-04-20 2020-02-28 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
CN110283779A (en) * 2019-07-17 2019-09-27 吉林省农业科学院 A kind of isolated culture method and culture medium of chicken embryonic stem cells

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010227A1 (en) * 1991-11-14 1993-05-27 Charles Weissmann Transgenic animals lacking prion proteins
WO1993023528A1 (en) * 1992-05-15 1993-11-25 North Carolina State University Avian embryonic stem cells
WO1994025585A1 (en) * 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1998022510A2 (en) * 1996-11-18 1998-05-28 Arch Development Corporation Methods for the production of chicken monoclonal antibodies
WO1998024893A2 (en) * 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
WO1998024884A1 (en) * 1996-12-02 1998-06-11 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies
WO1999006534A1 (en) * 1997-08-04 1999-02-11 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, Represented By Its Amherst Campus Production of avian embryonic germ (eg) cell lines by prolonged culturing of pgcs, use thereof for cloning and chimerization
WO1999019472A1 (en) * 1997-10-16 1999-04-22 University Of Georgia Research Foundation, Inc. Vectors comprising a magnum-specific promoter for avian transgenesis
WO2000046251A2 (en) * 1999-02-05 2000-08-10 Buelow Jens Ulrich Human polyclonal antibodies from transgenic nonhuman animals

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010227A1 (en) * 1991-11-14 1993-05-27 Charles Weissmann Transgenic animals lacking prion proteins
WO1993023528A1 (en) * 1992-05-15 1993-11-25 North Carolina State University Avian embryonic stem cells
WO1994025585A1 (en) * 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1998022510A2 (en) * 1996-11-18 1998-05-28 Arch Development Corporation Methods for the production of chicken monoclonal antibodies
WO1998024884A1 (en) * 1996-12-02 1998-06-11 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies
WO1998024893A2 (en) * 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
WO1999006534A1 (en) * 1997-08-04 1999-02-11 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, Represented By Its Amherst Campus Production of avian embryonic germ (eg) cell lines by prolonged culturing of pgcs, use thereof for cloning and chimerization
WO1999019472A1 (en) * 1997-10-16 1999-04-22 University Of Georgia Research Foundation, Inc. Vectors comprising a magnum-specific promoter for avian transgenesis
WO2000046251A2 (en) * 1999-02-05 2000-08-10 Buelow Jens Ulrich Human polyclonal antibodies from transgenic nonhuman animals

Also Published As

Publication number Publication date
AU7491800A (en) 2001-04-17
WO2001019394A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
WO2001019394A3 (en) Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
DK1212422T3 (en) Human CTLA-4 antibodies and their uses
ATE301471T1 (en) USE OF ANTIBODIES AGAINST CD45RO LEUKOCYTE ANTIGEN FOR IMMUNE MODULATION
DK0979246T3 (en) Human monoclonal antibodies against epidermal growth factor receptor
CA2328851A1 (en) Humanized immunoglobulins and their production and use
EP0332424A3 (en) Chimeric antibodies directed against human carcinoembryonic antigen
DK0853661T3 (en) Specific binding elements for human transforming growth factor beta; materials and methods therefor
RU2006143686A (en) ANTIBODIES
AU2907200A (en) Human polyclonal antibodies from genetically engineered animals
WO2003081993A3 (en) Transgenic aves producing human polyclonal antibodies
AU5215090A (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DE69824234D1 (en) Human "CDR-grafted" antibodies to ganglioside gm2
SE8601644D0 (en) ANTIBODY PREPARATION AGAINST CERTAIN DETERMINANTS IN HUMAN C3 AND ITS USE AND PREPARATION
NO870476L (en) PROCEDURE FOR THE PREPARATION OF CROSS PROTECTIVE HUMAN MONOCLONAL ANTIBODY PREPARATIONS.
ATE251667T1 (en) VIRUS THAT CAUSES PANCREAS DISEASE IN FISH
SE9201281D0 (en) NEW HUMAN MONOCLONAL ANTIBODIES, AND A METHOD FOR PREPARATION THEREOF
NO883603L (en) HUMAN MONOCLONAL ANTIBODIES AND PROPHYLACTIC AND THERAPEUTIC AGENTS FOR INFECTIOUS DISEASES INCLUDING THESE EFFECTIVE COMPONENT.
DE10080481D2 (en) Specific IgY egg yolk antibodies, their extraction and their use
MX9202912A (en) NEW MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VIRUSES OF HUMAN IMMUNOSUFFICIENCY AND THE PROCESS FOR ITS PREPARATION.
NO930406D0 (en) SPECIFIC ANTIBODIES AGAINST ACTIVATED BLOOD PLATES AND MANUFACTURING
TH58465B (en) Antibodies to human CD40
Arnouts Somatostatin immunoneutralization in the chicken: Immunogen development and effect on growth.
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
TH83888B (en) Humanized beta-amyloid peptide specific antibodies
TH58465A3 (en) Antibodies to human CD40

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP